Journal profile · MEDICINE, RESEARCH & EXPERIMENTAL
Advances in Clinical and Experimental Medicine
ISSN 1899-5276 · eISSN 2451-2680 · Wroclaw Medical University · POLAND · Founded 1998
Advances in Clinical and Experimental Medicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.46; fully open access; APC charged, amount not published; median 121 days to acceptance (111 articles, last 24 months); community-reported acceptance: easy; 123 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Advances in Clinical and Experimental Medicine is published by Wroclaw Medical University and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Oral microbiology and periodontitis research and Cancer-related molecular mechanisms research, together about 17.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Advances in Clinical and Experimental Medicine (Adv Clin Exp Med) is an international, peer-reviewed journal that highlights the full translational pathway of biomedical research – from laboratory discoveries (“bench”), through clinical application (“bedside”), to real-world practice and policy (“implementation”). The journal welcomes original research articles, reviews/meta-analyses, clinical recommendations/guidelines, research-in-progress reports, research letters, and study protocols authored by recognized experts in clinical and experimental medicine. The journal does not publish case studies, case series, and bibliometric studies. By embracing this translational continuum, Adv Clin Exp Med serves as a platform for studies that not only advance scientific knowledge but also demonstrate clear potential to improve patient outcomes and healthcare systems. We particularly value contributions that bridge gaps between experimental insights, clinical trials, and the implementation of evidence-based practices in diverse medical settings, especially those developed by international, multi-center research teams.
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTAL
Editor-in-chief Donata KurpasPublisher website
Editorial board by country: none in mainland China; most named Poland 11 (11 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology7.4%
- Oral microbiology and periodontitis researchDentistry5.2%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology4.6%
- Dental materials and restorationsDentistry4.5%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine4.5%
- Dialysis and Renal Disease ManagementMedicine4.3%
- Cardiovascular Function and Risk FactorsMedicine4.3%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedPublisher website
Other: Journal Impact Factor (JIF 2025) – 2.5, Journal Citation Indicator (JCI 2025) – 0.40, Index Copernicus Value (ICV 2024) – 161.00, MNiSW – 70 pts, Ulrich’s International Periodicals Directory, Index Copernicus, Journal Citation Reports/Science Edition
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.46LetPub ·
- Impact factor (publisher) 2025
- 2.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.3Publisher website ·
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore (publisher) 2025
- 4.2Publisher website ·
- SJR 2026-06
- 0.6LetPub ·
- SJR (publisher)
- 0.6Publisher website ·
- SNIP 2026-06
- 0.66LetPub ·
- h-index
- 21LetPub ·
- h-index
- 63OpenAlex ·
- i10-index
- 899OpenAlex ·
- 2-year mean citedness
- 2.05OpenAlex ·
- Self-citation rate
- 8%LetPub ·
- Share of gold OA articles
- 99.28%LetPub ·
Volume
- Articles per year
- 92LetPub ·
- Articles per year (publisher)
- 70Publisher website ·
Articles by year OpenAlex count · 2,572 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 156 | 156 | 36 |
| 2025 | 123 | 123 | 178 |
| 2024 | 167 | 167 | 701 |
| 2023 | 188 | 188 | 1,254 |
| 2022 | 181 | 181 | 1,899 |
| 2021 | 169 | 169 | 2,136 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
121 daysMedian, submission to acceptance · P25–P75 79 days – 175 days
- Acceptance to online
- median 99 days (28 articles)
- Submission to online
- median 201 days
- Sample
- 111 articles with submission and acceptance dates (397 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to publication (journal-reported)
- about 54 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 1,600 / PLN 6,900 | Yes | CC BY | |
| OpenAlex | EUR 700 | — | — | |
| LetPub | EUR 1,600 / PLN 6,900 | Yes | — | |
| Publisher website | EUR 1,600 / EUR 990 / EUR 700 / EUR 350 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted7, with length limits
- commentaryManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…main text ≤ 1,500 words
- editorialManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…Length not stated
- letterManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…main text ≤ 7,000 words
- meta-analysisManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…Length not stated
- original paperManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…main text ≤ 1,500 words
- protocolManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…Length not stated
- reviewManuscripts may be considered for publication in the following sections: Original papers – including experimental research Reviews Meta-Analyses Research-in-Pro…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Peer review, Preprints
- AI use Authorship and AI tools – COPE position statement
The use of artificial intelligence (AI) tools, such as ChatGPT or Large Language Models, in research publications is expanding rapidly. COPE joins organisations, such as WAME and the JAMA Network, among others, to state that AI tools cannot be listed as an author of a paper. AI tools cannot meet the requirements for authorship, as they cannot take responsibility for the submitted work. As non-lega…
Source ↗Publisher website ·- Authorship Authorship
Manuscript withdrawal policy: requires clear reason and consent of all authors. Model summary
No information allowing for authors' identification, in particular authors' names, should appear anywhere in the main body of the paper. All Authors who have made significant contributions should be listed as co-authors, and their authorship should be disclosed in the Editorial System under the following list: A – research concept and design; B – collection and/or assembly of data; C – data analys…
Source ↗Publisher website ·- Conflicts of interest Conflict of interest
Any conflict of interest should be reported while submitting the manuscript in a dedicated section of the submission procedure in our Editorial System, not in the Acknowledgements section or in the paper itself. All authors must provide disclosures before submission for inclusion in the “Conflict of Interest” statement. A conflict of interest exists when one’s professional judgment about the execu…
Source ↗Publisher website ·- Data availability Policy concerning data sharing
Adv Clin Exp Med requires the Authors of all original papers to make all data necessary to replicate their study's results publicly available without restriction when the paper is submitted to the journal (relevant information must be registered in the Editorial System at the time of submission). All the data and related metadata underlying the reported findings should be deposited in appropriate …
Source ↗Publisher website ·- Publication ethics If ethical approval applies, its number is included in the text.
Abbreviations explained in the text, not on a separate list.
Source ↗Publisher website ·- License & copyright Our copyright declaration
The Author/Author(s) declare that: a) they are copyright holders of the scientific work/publication; b) they are entitled to dispose of copyright for the concluded license/publishing agreement with the Wroclaw Medical University; c) they created the work/publication on their own; d) the work/publication does not violate the rights of third parties. If a third party files a claim against Wroclaw Me…
Source ↗Publisher website ·- Peer review
The journal does not publish case studies, case series, and bibliometric studies. Model summary
The journal does not publish case studies, case series, and bibliometric studies.
Source ↗Publisher website ·- Preprints Policy regarding preprints
Adv Clin Exp Med endorses and encourages the posting of manuscript preprints on non-profit preprint servers such as BioRxiv, MedRxiv, ResearchSquare, or Authorea, as well as on authors’ or institutional websites. Posting preprints is not considered a prior publication, and the manuscript can enter peer review at Adv Clin Exp Med following the regular procedure. Preprints are defined as an author’s…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wroclaw Medical University
- Country or region
- POLAND
- Language
- English
- Founded
- 1998
- ISSN
- 1899-5276
- Electronic ISSN
- 2451-2680
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Advances in Clinical and Experimental Medicine
What CAS zone is Advances in Clinical and Experimental Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Advances in Clinical and Experimental Medicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Advances in Clinical and Experimental Medicine?
The latest impact factor listed by LetPub is 2.46; CiteScore 4.2, h-index 63.
How long does peer review take at Advances in Clinical and Experimental Medicine?
Based on the dates recorded on 111 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 121 days (interquartile range 79–175 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Advances in Clinical and Experimental Medicine based?
Of the 11 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Poland (11). Counted from the institutions listed on the board page; for reference only.
Which databases index Advances in Clinical and Experimental Medicine?
According to LetPub and DOAJ records, Advances in Clinical and Experimental Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE and PubMed; that list has not been checked against each database.
Is Advances in Clinical and Experimental Medicine open access, and what is the APC?
Advances in Clinical and Experimental Medicine is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .